



Virtual Standard High Resolution Anoscopy Course Program

The Virtual Standard High Resolution Anoscopy Course will be open **March 1** through **November 30, 2024**. This is a self-paced course with pre-recorded thematic modules that can be completed at any time during the period the course is open.

You can submit questions to the [HRA Q&A Forum](#). Make sure to include the **Module number, name of instructor** and the **title of the lesson** in your question.

Educational Objectives

This course has been designed to improve competencies in medical knowledge, practice-based learning, systems-based practice, and patient care.

- To describe the epidemiology and pathophysiology of anal HPV-associated disease including HPV infection, low- and high-grade squamous intraepithelial lesions (L/HSIL), anal cancer.
- To identify populations who may benefit from anal cancer screening.
- To teach the diagnostic procedures used in the evaluation of L/HSIL and anal cancer. These include anal cytology, digital anal rectal exam, high resolution anoscopy, anal biopsy and ablative therapies.
- To discuss different treatment and management options for L/HSIL and anal cancer.
- To discuss prevention strategies for HPV-associated disease.

Continuing Medical Education Credits

ACCME Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The American College of Obstetricians and Gynecologists and International Anal Neoplasia Society. The American College of Obstetricians and Gynecologists is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Category 1 Credit(s)[™]

The American College of Obstetricians and Gynecologists designates this enduring activity for a maximum of **18.5 AMA PRA Category 1 Credits.**[™] Physicians should claim only the credit commensurate with the extent of their participation in the activity.

College Cognate Credit(s)

The American College of Obstetricians and Gynecologists designates this enduring activity for a maximum of **18.5** Category 1 College Cognate Credits. The College has a reciprocity agreement with the AMA that allows **AMA PRA Category 1 Credits**[™] to be equivalent to College Cognate Credits.

Instructions for Obtaining Continuing Medical Education Credit

To complete this program successfully and receive credit and a certificate of attendance, participants must:

- Read the program objectives
- Complete the online content (which will be made available until **November 30, 2024**)
- Complete the conference evaluation form online upon completion of the course

CME Certificates

The evaluation must be completed by **November 30, 2024** in order to receive your CME certificate. We will be unable to process CMEs after this date. Please contact IANS with questions or concerns at kelli.welsh@iansociety.org.

Faculty List

Course Planning Committee

Julie Bowring, MD

Consultant Gynecologist Homerton Anal Neoplasia Service, Homerton University Hospital, London, United Kingdom

Cristina Brickman, MD

Assistant Clinical Professor of Medicine, Division of Infectious Diseases, Department of Medicine, UCSF, San Francisco, California, USA

Tamzin Cuming, MD

Consultant Colorectal Surgeon, Homerton University Hospital London, United Kingdom

Naomi Jay, RN, NP, PhD

Assistant Clinical Professor of Nursing, UCSF, San Francisco, California, USA

Course Faculty

J. Michael Berry-Lawhorn, MD

Clinical Professor of Medicine, UCSF, San Francisco, California, USA

Teresa Darragh, MD

Professor of Clinical Pathology, UCSF, San Francisco, California, USA

Stephen E. Goldstone, MD

Assistant Clinical Professor of Surgery, Icahn School of Medicine at Mount Sinai, New York City, New York, USA

Richard Hillman, MD

Associate Professor, HIV, Immunology & Infectious Disease, St Vincent's Hospital and The Kirby Institute for Infection & Immunity in Society, Sydney, Australia

Michelle Khan, MD

Clinical Associate Professor and Director of the Anogenital Dysplasia Clinic at Stanford University School of Medicine, Stanford, California, USA

Joel M. Palefsky, MD

Professor of Medicine, UCSF, Director, ANCRE Clinic UCSF, San Francisco, California, USA

Invited Speakers

Luis Barroso, MD

IANS President and Associate Professor Wake Forest Baptist Health, Winston-Salem, North Carolina, USA

Gary Bucher, MD

Medical Director and founder of the Anal Dysplasia Clinic MidWest, Chicago, Illinois, USA

Megan Clarke, PhD

National Cancer Institute - Division of Cancer Epidemiology and Genetics, Bethesda, Maryland, USA

Gary Clifford, PhD

Cancer Epidemiologist, International Agency for Research on Cancer, Lyon, France

Troy Grennan, MD, FRCPC

Clinical Assistant Professor, Medicine, University of British Columbia, Vancouver, Canada

Jessica Korman, MD

Gastroenterologist, Capital Digestive Care, Washington D.C., USA

Helle Kiellberg Larsen, MD, PhD

Department of Dermato-venereology, Bispebjerg Hospital, Copenhagen, Denmark

Carmella Law, MD

Sexual Health Physician, St. Vincent's Hospital, Sydney, Australia

Rosalyn Plotzker, MD

Assistant Professor, Epidemiology & Biostatistics, UCSF, San Francisco, California, USA

Elena Sendagorta-Cudós, MD

Universidad Autónoma de Madrid, Madrid, Spain

Elizabeth Stier, MD

Department of Obstetrics and Gynecology Boston Medical Center, Boston Massachusetts, USA

Richard Turner, MD

Professor of Surgery, University of Tasmania, Hobart, Tasmania, Australia

Jackie Wang, MD

Assistant Professor, Medicine UCSF, San Francisco, California, USA

Module 1 - HPV Background (Epidemiology, Pathogenesis and Anatomy)

Objectives:

- Apply knowledge of lower genital HPV infection, including natural history, to the anal canal
- Describe anal canal and perianal anatomy
- Define and identify histopathological and cytopathological features of anal squamous intraepithelial lesions and anal cancer

1. Introduction to HPV: General Epidemiology - 30 mins
2. Epidemiology of Anal Cancer and Squamous Intraepithelial Lesions (SIL) – 31 mins
3. Anal Anatomy – 13 mins
4. Pathology 1: Anal Squamous Intraepithelial Lesions and Cancer – 30 mins
5. Pathology 2: Interpretation of Anal Cytology – 26 mins

Total time: approximately 2 hours

Module 2 - Introduction to HRA and Related Procedures

Objectives:

- Understand and define terminology related to HRA
- Interpret the normal features encountered during HRA with respect to the transformation zone and anal/perianal anatomy
- Learn the steps of performing an HRA exam and related procedures

1. HRA Terminology – 26 mins
2. HRA: Features of the Normal Anal Transformation Zone – 21 mins
3. HRA Procedures/Skills – 45 mins
4. Putting it together: HRA Video – 25 mins

Total time: approximately 2 hours

Module 3 - HRA Pattern Recognition

Objectives:

- Identify and differentiate Low-grade (L)SIL and High-grade (H)SIL within the anal canal and perianus
- Recognize features of invasive disease

1. HRA: Identification of LSIL – 20 mins
2. HRA: Identification of HSIL – 26 mins
3. HRA: Identification of Perianal Lesions – 28 mins
4. HRA: Identification of Cancer – 33 mins
5. Tips to improving HRA skills – 31 mins

Total time: approximately 2.2 hours

Module 4 - Treatment of ASIL

Objectives:

- Summarize current treatment options for Anal SIL including topical, ablative and excisional methods
- Describe their mode of action, benefits and complications
- Requirements for anesthesia associated with different treatment modalities

1. Principles of Treatment – 24 mins
2. Topical Therapies – 30 mins
3. Ablative Therapies: Technique – 49 mins
4. Anesthesia for Procedures – 11 mins

Total time: approximately 2 hours

Module 5 - Screening for HPV-associated Lesions

Objectives:

- Summarize the key principles of screening
 - Recognize how current screening criteria are used in anal cancer screening and anal cancer precursor screening
 - Identify high-risk groups appropriate for screening
1. The WHO Screening Criteria – 35 mins
 2. Judging who to screen for prevention of anal cancer: where do we stand today - 39mins
 3. Screening Tests for anal cancer: Current approaches and future directions – 30 mins
 4. Screening for anal cancer: IANS Consensus guidelines – 18 mins

Total time: approximately 2 hours

Module 6 - Management of Anal Cancer

Objectives:

- Describe the standard of care for treatment of invasive anal cancer
 - Recognize the indications for and risks of conservative treatment for early anal cancer
 - Understand the management for recurrent anal cancer
 - Define the role of HRA following treatment of anal cancer
1. Anal Cancer Treatment - 31 mins
 2. HRA following Cancer – 14 mins

Total time: approximately 45 mins

Module 7 - Management and Counseling

Objectives:

- Outline appropriate management for anal SIL including treatment in the operating room, and follow-up post-treatment
- Understanding the impact of anal neoplasia on patients

1. Treatment Triage: Cases – 44 mins
2. HRA in the Operating Room: Two Perspectives – 34 min
3. Messaging: Counseling the Patient with HPV-associated Disease – 28 mins
4. The Patient's Perspective – 32 min

Total time: approximately 2.3 hours

Module 8 - Practicalities for Establishing an HRA Practice

Objectives:

- Define components of an HRA practice
- Recognize practice metrics, practice standards and international guidelines
- Describe the indications for HPV vaccination

1. Essential Equipment for HRA – 21 mins
2. Documentation for HRA – 22 mins
3. Guidelines for Creating a New HRA Practice – 21 mins
4. HRA Practice Metrics – 30 mins
5. HPV Vaccination for prevention – 28 min

Total time: approximately 2 hours

Module 9 - Anal Neoplasia in Context

To receive full CMEs please choose a minimum of 3 topics (subjects noted as optional do not count towards CMEs)

Objectives:

- Expand knowledge to that of other specialty areas that overlap with management of lower anogenital tract disorders
1. Non-infectious Disease of the Anus and Perianus – 39 mins
 2. Vulvar Disease – 31 mins
 3. Sexually Transmitted Infections, Testing and Treatment – 24 mins
 4. Diseases of the Colon and Rectum – 29 mins
 5. Dermatologic conditions – 26 mins
 6. Coding and Billing (US based providers) **Optional** – 34 mins
 7. HRA and Cervical Colposcopy: Differences **Optional** – 23
 8. Incorporating research into clinical practice **Optional** – 11 mins